Nitta Gelatin India Ltd (506532) — மல்டிபேக்கர் பகுப்பாய்வு

1. ராம்ப்-அவேர் தாக்கக் கணக்கீடு

• Capacity Analysis: The newly commissioned Collagen Peptide Project has an installed capacity of 3.5 MT/day. Assuming 300 operational days, this translates to ~1,050 Metric Tonnes Per Annum (MTPA).
• Revenue Estimation: Assuming a conservative realization of ‹8.5 Lakhs per MT for specialized collagen peptide, the peak revenue potential is ~‹90 Crore.
• Ramp-up Schedule:
• Year 1 (FY27): 55% capacity utilization yields ~‹50 Crore in incremental revenue (~8.5% uplift over TTM revenue of ‹589 Crore).
• Steady-State (FY28): 85% capacity utilization yields ~‹76.5 Crore in incremental revenue (~13.0% uplift).
• Margin & EPS Impact: While current TTM OPM is high at 23.1%, management has guided for long-term sustainable margins of 12-15% due to global supply-demand dynamics. Assuming a blended steady-state OPM of 18% for this premium peptide project, incremental operating profit would be ~‹13.8 Crore. At a 25% tax rate, this adds ~‹10.3 Crore to PAT, translating to an EPS uplift of ~10.0% on the current base.

2. தொழில்துறை மூலதனத் தீவிரம் & CAGR

• Capital Intensity: Medium. The company is investing ‹155 Crore for its gelatin expansion and has already completed the peptide project. Pledged assets have risen to ‹536.05 Crore to secure these expansions.
• Industry CAGR: The Indian nutraceutical market is growing structurally at a 20.35% CAGR. This provides a strong secular tailwind for collagen peptide and capsule-grade gelatin.

3. மல்டிபேக்கர் தர மதிப்பீடு

• Financials: Outstanding ROCE of 28.0% and virtually zero net debt (D/E of 0.01). Promoter holding is exceptionally strong and stable at 74.5%.
• Earnings Momentum: Quarterly PAT has accelerated from ‹19 Crore (Jun 2025) to ‹34 Crore (Mar 2026), driven by high capacity utilization and favorable pricing.
• The Margin Overhang: The primary risk to the multibagger thesis is management's own guidance of 12-15% sustainable margins. If margins mean-revert from the current 23.1% to 15%, earnings growth will stagnate despite volume expansions.

4. சூழ்நிலைப் பகுப்பாய்வு

• Base Case (35% Upside): Peptide project ramps up to 80% utilization; gelatin expansion progresses on schedule; blended margins moderate gently to 18% rather than crashing to 15%.
• Bull Case (75% Upside): High-value capsule-grade gelatin and peptides protect margins above 22%; BPL subsidiary resumes operations ahead of schedule; parent company's 2033 vision triggers a valuation re-rating toward the peer median P/E of 35.5x.
• Bear Case (-25% Downside): Global hide gelatin glut forces margins down to 12%; BPL shutdown extends beyond 18 months; US tariffs worsen, impacting 17% of revenue.

5. தீர்ப்பின் காரணம்

Nitta Gelatin is a high-quality business with stellar ROCE and strong parentage. However, the stock has already run up ~128% in the last 6 months, pricing in much of the near-term earnings acceleration. Given the looming margin mean-reversion risk and the long-term nature of the parent's doubling target (by 2033), it is classified as a 'POSSIBLE' multibagger rather than a 'STRONG_CANDIDATE'. It remains an excellent compounder with solid downside protection.